Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66).

Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5.

PRINCETON, N.J. and SUZHOU, China, April 10, 2024 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented 4 posters highlighting study results from ongoing trials related to Osemitamab (TST001) and TST003 at AACR Annual Meeting 2024, including development of Claudin18.2 IHC 14G11 pharmDx as a clinical trial assay for the clinical development of anti-Claudin 18.2 monoclonal antibody Osemitamab (TST001) in G/GEJ adenocarcinoma; the safety, tolerability and pharmacokinetics profile of Osemitamab (TST001) administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors (TranStar101: a Phase I/IIa clinical trial); prevalence of Claudin18.2 expression in gastric/gastroesophageal junction adenocarcinoma by Transcenta proprietary CLDN18.2 assay from US and Chinese patients from Transtar101 and Transtar102 clinical trials, as well as a first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumors.

PRINCETON, N.J. and SUZHOU, China, April 9, 2024 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilent Technologies , announce a collaboration to develop a Claudin 18.2(CLDN 18.2) companion diagnostic to support TranStar301 global Phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line treatment in patients with CLDN 18.2 expressing locally advanced or metastatic gastric or gastroesophageal (G/GEJ) adenocarcinoma.

PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2023 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the preclinical anti-tumor efficacy and safety results of [177Lu]Lu-TST001 have been published on European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI). In this preclinical studies, [177Lu]Lu-TST001 demonstrated significant antitumor efficacy with acceptable toxicity. It exhibits strong potential for clinical translation, providing a new promising treatment option for CLDN18.2-overexpressing tumors, including gastric cancer.

Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all patients treated in the expansion cohort